Objectives: Common Variable Immunodeficiency Disorders (CVID) and Large Granular Lymphocytes leukemia (LGLL) exhibit diverse clinical manifestations including infections, dysimmunity, and lymphoproliferation. Recent decades have seen the discovery of new genes in the lymphopoiesis pathway, such as JAK-STAT. This case series supplemented by a literature review aims to describe clinical and biological characteristics of patients with both CIVD and LGLL.

Methodology: Patients were included through a call for comments to French and Belgian centers and through a literature review via PubMed. Clinical characteristics were compared to two large French cohort involving CVID and LGLL patients.

Results: Twelve patients were included. In all cases, CVID precedes LLGL (median diagnosis delay for LLGL was 7 years). Most cases presented with splenomegaly and autoimmune cytopenia. Ten out of 12 patients underwent splenectomy during follow up.

Conclusions: Patients with LGLL and CVID differ from patients without immune deficiency in term of clinical presentation and prognosis. We suggest CVID may act as a trigger of LGL lymphocytosis, due to endogenous and exogenous antigenic pressure leading to the selection of a dominant LGL clone and stimulation of the JAK-STAT pathway. The role of splenomegaly and splenectomy in LGLL onset warrant further investigation in future studies.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.14265DOI Listing

Publication Analysis

Top Keywords

large granular
8
immunodeficiency disorders
8
literature review
8
patients included
8
patients
6
cvid
5
characteristics large
4
granular lymphocyte
4
lymphocyte leukemia
4
leukemia associated
4

Similar Publications

Article Synopsis
  • Estimates indicate significant variation in R&D costs, with 20 large firms comprising 80.8% of patient-months and showing lower costs per patient-month compared to smaller firms.
  • A novel methodology was used to analyze R&D costs per drug, focusing on discrete units of activity related to clinical trials and using data from 268 US publicly traded drug developers.
  • The study found that R&D costs per new drug averaged around $1.31 billion, with a lower median cost of $708 million, highlighting a skewed distribution of expenses related to drug development.
View Article and Find Full Text PDF

The aims of the present study were to: (i) quantify accelerations and decelerations of soccer players during match-play across two consecutive seasons from the English Premier League (EPL) and Ligue 1 (L1); and (ii) compare any positional differences between the two leagues. Fifty-eight male professional soccer players were monitored during all league matches (n = 144) across seasons 2020/21 and 2021/22. The absolute number of accelerations (> +3 m/s) and decelerations (< -3 m/s) and accelerations and decelerations per minute were examined.

View Article and Find Full Text PDF

Prolonged use of antiretroviral agents has been clearly associated with nephrotoxicity, suggesting deterioration of renal function in patients receiving Highly Active Antiretroviral Therapy (HAART). The present study was designed to investigate the therapeutic efficacy of resveratrol (RV) in the treatment toxins-induced renal impairment. Twenty-four adult male Wistar rats weighing 70-90 g were divided into four groups and subjected to the following treatments: Control A (distilled water), B (HAART), C (RV-2.

View Article and Find Full Text PDF

Microbial loss significantly affects wastewater treatment efficiency. This study simulated the inoculation area of a self-developed biological doubling reactor (BDR) to evaluate the retention efficiency of seven different fillers for aerobic denitrifying bacteria. Over 90 days of continuous operation, the porous filler R3 demonstrated excellent performance, with OD values consistently exceeding 1.

View Article and Find Full Text PDF

Background: Health economic evaluations require cost data as a key input, and reimbursement policies and systems should incentivize valuable care. Subfertility is a growing global phenomenon, and Dutch per-treatment DRGs alone do not support value-based decision-making because they don't reflect patient-level variation or the impact of technologies on costs across entire patient pathways.

Methods: We present a real-world micro-costing analysis of subfertility patient pathways (n = 4.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!